Kyle LaHucik’s Post

Bob Nelsen, co-founder of ARCH Venture Partners, emphasizes the firm's pursuit of home runs in drug development.... ...ARCH's recent $3 billion fund, slightly larger than the previous $2.97 billion fund, reflects the firm's focus on groundbreaking ventures like AI bio Xaira Therapeutics. This spring, Xaira Therapeutics raised $1 billion, marking one of biotech's largest company launches... ...Nelsen highlighted the thorough diligence process by LPs, despite the challenging investment landscape. Noteworthy developments coincide with ARCH's fund announcement, including a potential FDA approval for a schizophrenia treatment from one of its neuroscience bets. The firm's strategic approach continues to draw attention in the venture capital landscape, alongside recent fund announcements by other industry players. ARCH Venture Partners #advancedtherapies #funding #financing #biotech #biotechnology #regenerativemedicine #lifesciences #lifescience #celltherapy #genetherapy #geneticmedicine Bain Capital Flagship Pioneering #venturecapital #duediligence

More dry powder added to the mix! ...About 50% of its portfolio is small molecules, 20% cell and gene therapies, 20% biologics and 10% oligonucleotides, according to the presentation. Rare disease comprises the biggest share at 36%, followed by oncology at 31%. Venture creation is the “vast majority of the deals” that Atlas Venture works on, Booth said, noting the firm doesn’t plan to grow much organizationally and will continue to be “science-first investors.” It added 18 new portfolio companies in 2023 and 2024, and deployed $420 million over that time..... #funding #financing #venturefunding #celltherapy #genetherapy #geneticmedicine #venturecreation #advancedtherapies #450m #UniversityofAlabama #Crain’sPensions #biotech #biotechnology #lifescience #lifesciences #sciencefirst #earlyfunding #portfoliocompanies

Founders often get crushed by dilution when raising a Series A. Dilution is a product of capital raised and company valuation. Curie.Bio helps founders minimize dilution by maximizing progress with less capital. By reaching critical milestones on blockbuster TPPs, you can raise more capital at a much higher valuation. Last fall, our first portfolio company, Forward Therapeutics, Inc., raised a $50M Series A to generate clinic data. A recent Oppenheimer report revealed this raise was the BIGGEST valuation step up compared to all other therapeutics companies that raised a Series A in the last 12 months. The best part? The founders retained significant ownership in their company. That's the power of the Curie.Bio model. That's how we #freethefounders. If you have an exciting therapeutic idea, we'd love to collaborate. Contact our team or visit our website. https://lnkd.in/e4NWnqwF

The pandemic was a challenging period for all. But it also offered us opportunities! The concept of Jupiter is a great example. Jupiter Bioventures, a product of virtual brainstorming with friends (Ned David, Ned Sharpless and Steve Tregay) to enable Mayo Clinic’s insatiable desire to create the next generation of Cures, is now a powerhouse of drug development that has attracted value-aligned investors and academic partners to join forces in the best interest of patients everywhere…. Congratulations Jupiter team! May the patients win….. Norman Sharpless Nathaniel David Steve Tregay Nirdesh K Gupta, PhD Steven VanNurden Peter Noseworthy, MD Vijay Shah Heidi Dieter Andy Danielsen Mayo Clinic Ventures James Rogers Clark Otley Olayemi (Yemi) Sokumbi, M.D. Pankaj Jay Pasricha Waleed Brinjikji Janani Reisenauer Justin Butler Geoff Johnson, MD, PhD Melissa Noel, MBA, MSE, Johannes Fruehauf, Owen Garrick, MD, Jeanette Caban Cheryl Willman, M.D. #venture, #biopharma, #capital, #venturecapital #accelerator, #drug #drugdevelopment, #development, #technology, #commercialization, #technologytransfer, #research, #clinicaltrial, #patient, #cure, #transform, #venturestudio, #disease, #cancer

Izmu - Sample Seed pitch deck: Feel Therapeutics's $3.5M deck

We’re excited to officially launch Jupiter Bioventures, a pioneering biotechnology venture foundry building bold, science-driven therapeutics companies. Co-Founders Nathaniel David, PhD, and Norman Sharpless, MD, bring decades of industry experience to drive a scalable foundry model, advancing #biotech innovation in #cancer and other areas in which insights from cancer biology provide insight. With $70 million raised from returning investors Mission BioCapital and Mayo Clinic alongside #lifescience investors Alexandria Venture Investments, Bioventure Partners, Cedars-Sinai Intellectual Property Company, CU Healthcare Innovation Fund, Eric Ball, Eshelman Ventures, LLC, Fox Ventures, The Brent and Julie Callinicos Trust and Vault Fund, Jupiter will found, launch, and operate multiple therapeutics companies. https://lnkd.in/eaUJsaE8 Stay tuned as we pursue breakthrough science to deliver #innovation in life sciences.

San Francisco-based Foresite Capital ,led by founder and CEO Jim Tananbaum has closed its sixth fund with $900 million in capital commitments, emphasizing its dedication to advancing healthcare and life sciences technologies. Fund VI has attracted a diverse group of global investors, reflecting strong confidence in Foresite Capital's strategy. The firm will focus on precision therapeutics, life science infrastructure, and healthcare delivery. Founded in 2011, Foresite Capital manages over $3.5 billion in assets and has a notable track record, including 47 IPOs and 58 FDA-approved drugs. The fund's portfolio features promising companies like Alumis and CG Oncology. #ForesiteCapital #HealthcareInvestment #LifeSciences #PrecisionTherapeutics #BiotechInnovation #InvestmentFund #HealthcareDelivery #VentureCapital #FundVI #BiotechInvesting #startup77

Are IPOs the Next Big Leap for Biotech Innovations? 💡 | As biotech companies CAMP4 Therapeutics and Upstream Bio carve out their ambitions with planned IPOs worth $67 and $182 million respectively, the industry is abuzz with potential game-changing developments. But this begs the question - will these bold milestones truly accelerate innovation or are they part of a bigger trend in the biotech sector? Ready to make waves in your industry too? With Bridgewise's expertise, you can power up your innovations 🚀. Fast-track development of AI solutions and stay ahead of competition! Looking at expanding your business horizons across Europe or United States? Let’s find those golden opportunities together! Being a global corporate development network with access to 160K+ top decision-makers including venture builders from diverse industries, we connect startup founders with angel investors or VCs. The goal at Bridgewise is simple: help innovative tech founders grow their companies significantly by providing critical insights & resources. Click here for more details on CAMP4 and Upstream Bio's big plans 👉 https://lnkd.in/eH3sazsx #Biotech #CAMP4Therapeutics #UpstreamBio #IPO #InnovationAcceleration #TechFounders #InvestorsConnection #GlobalExpansionOpportunities #VentureGrowth

Gene&Cell Therapy >> Cormorant nears the close of fifth private healthcare fund as biotech industry sees greener pastures: Cormorant Asset Management has been on a tear lately. The Boston-based firm plans to close its fifth private healthcare fund this month, founder Bihua Chen said. The firm has reached its $400 million target for the fund, Chen told Endpoints News on Friday. The investment firm, a little over a decade old, has taken part in multiple megarounds for biotechs in recent weeks for a variety of areas (epilepsy cell therapy, oncology small molecules, plus a muscle-preserving weight loss combination treatment) and successfully brought its second special purpose acquisition company onto the Nasdaq when many other investors backed away. Cormorant was one of the top 10 most active private biopharma investors of 2023, per a January report from investment bank William Blair. The firm is also a shareholder in some companies that have gone public in recent quarters, including CARGO Therapeutics and Neumora Therapeutics, per SEC paperwork. “Given my public market experience, Cormorant was started as a hedge fund, but I had always had interest in private investing because we have always been long term-focused,” Chen said. The firm started investing in the private markets about two years after launching and hit a key milestone in December 2015 with its first separate private fund. Chen has had a strong pulse on the industry for many years and sees across an array of innovations via board seats at more than a dozen medical device and biotechnology companies, per SEC filings. That covers epigenetic editing startup Chroma Medicine, Sam Waksal-led Graviton Bioscience, US and Belgian molecular glue maker Orionis Biosciences, and medical device companies like Myra Vision and Akura Medical. Cormorant is also hunting for the next biotech company to combine its second SPAC with after its first one helped bring MoonLake Immunotherapeutics onto the Nasdaq. Chen wants the “same rigor in terms of science and data and a commercial aspect” for a SPAC combination target. “It’s not extra work in terms of finding this company because Cormorant is constantly looking for this kind of company to begin with,” Chen said. “The extra work in execution, we’ve done it before. We are experienced in that.” #lucidquest #genetherapy #celltherapy

TPG has closed a $580 million life sciences fund for drug development startups, medical device makers and tech-enabled healthcare services companies. The fund has already backed multiple biotechs, including antibody-drug conjugates maker MBrace Therapeutics, immunology startup Santa Ana Bio, TYK2 drug developer Sudo Biosciences and oncology-focused Bicara Therapeutics, among others. Leading the fund’s investment team are partners Carolyn Ng, Shinichiro Fuse and Lucian Iancovici MD. TPG's Life Sciences Innovation unveiling on Tuesday follows a $650 million fund at Goldman Sachs, a $500 million-plus fund at JP Morgan and about two dozen funds from biotech and life sciences specialists so far this year. More in Endpoints News: #tpg #lifesciences #biotechinvesting #biotech